Cull G M, Timms J M, Haynes A P, Russell N H, Irving W L, Ball J K, Thomson B J
Department of Clinical and Laboratory Sciences, University of Nottingham at Nottingham City Hospital.
Br J Haematol. 1998 Mar;100(4):793-6. doi: 10.1046/j.1365-2141.1998.00671.x.
Dendritic cells (DC) are antigen-presenting cells with the potential to be a powerful adjuvant in the immunotherapy of haematological malignancy, including myeloma. Recently, human herpesvirus 8 (HHV-8) infection of dendritic cells in the long-term bone marrow stromal cultures of patients with myeloma has been reported. This finding is of great potential importance regarding oncogenesis in myeloma in addition to having significant implications for the use of DC in the immunotherapy of this disease. Therefore DC generated from mobilized blood mononuclear cells (MO-DC) and purified CD34+ cells (CD34-DC) of myeloma patients were examined for the presence of HHV-8 using a sensitive PCR technique. HHV-8 was not demonstrated in MO-DC or CD34-DC and we conclude that these cells remain a suitable vehicle for investigation in the immunotherapy of myeloma.
树突状细胞（DC）是抗原呈递细胞，在包括骨髓瘤在内的血液系统恶性肿瘤免疫治疗中有可能成为强大的佐剂。最近，有报道称在骨髓瘤患者的长期骨髓基质培养物中，树突状细胞受到了人类疱疹病毒8型（HHV-8）感染。这一发现除了对DC在该疾病免疫治疗中的应用具有重要意义外，对于骨髓瘤的肿瘤发生也具有极大的潜在重要性。因此，使用灵敏的聚合酶链反应（PCR）技术检测了骨髓瘤患者动员的血液单核细胞（MO-DC）和纯化的CD34+细胞（CD34-DC）产生的DC中HHV-8的存在情况。在MO-DC或CD34-DC中未检测到HHV-8，我们得出结论，这些细胞仍是骨髓瘤免疫治疗研究的合适载体。
